These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15650859)

  • 21. Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study.
    Schoenberger J; Grimm D; Kossmehl P; Infanger M; Kurth E; Eilles C
    Endocrinology; 2004 Mar; 145(3):1031-8. PubMed ID: 14607854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis.
    Schomber T; Zumsteg A; Strittmatter K; Crnic I; Antoniadis H; Littlewood-Evans A; Wood J; Christofori G
    Mol Cancer Ther; 2009 Jan; 8(1):55-63. PubMed ID: 19139113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma.
    Brandes AA; Stupp R; Hau P; Lacombe D; Gorlia T; Tosoni A; Mirimanoff RO; Kros JM; van den Bent MJ
    Eur J Cancer; 2010 Jan; 46(2):348-54. PubMed ID: 19945857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584.
    Thomas AL; Morgan B; Drevs J; Unger C; Wiedenmann B; Vanhoefer U; Laurent D; Dugan M; Steward WP
    Semin Oncol; 2003 Jun; 30(3 Suppl 6):32-8. PubMed ID: 12802793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy.
    Hess-Stumpp H; Haberey M; Thierauch KH
    Chembiochem; 2005 Mar; 6(3):550-7. PubMed ID: 15742376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth.
    Duh EJ; Yang HS; Suzuma I; Miyagi M; Youngman E; Mori K; Katai M; Yan L; Suzuma K; West K; Davarya S; Tong P; Gehlbach P; Pearlman J; Crabb JW; Aiello LP; Campochiaro PA; Zack DJ
    Invest Ophthalmol Vis Sci; 2002 Mar; 43(3):821-9. PubMed ID: 11867604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization.
    Ozaki H; Seo MS; Ozaki K; Yamada H; Yamada E; Okamoto N; Hofmann F; Wood JM; Campochiaro PA
    Am J Pathol; 2000 Feb; 156(2):697-707. PubMed ID: 10666398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of PTK/ZK on the angiogenic switch in head and neck tumors.
    Miyazawa M; Dong Z; Zhang Z; Neiva KG; Cordeiro MM; Oliveira DT; Nör JE
    J Dent Res; 2008 Dec; 87(12):1166-71. PubMed ID: 19029087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging.
    Drevs J; Müller-Driver R; Wittig C; Fuxius S; Esser N; Hugenschmidt H; Konerding MA; Allegrini PR; Wood J; Hennig J; Unger C; Marmé D
    Cancer Res; 2002 Jul; 62(14):4015-22. PubMed ID: 12124335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PTK787/ZK22258 attenuates stellate cell activation and hepatic fibrosis in vivo by inhibiting VEGF signaling.
    Liu Y; Lui EL; Friedman SL; Li L; Ye T; Chen Y; Poon RT; Wo J; Kok TW; Fan ST
    Lab Invest; 2009 Feb; 89(2):209-21. PubMed ID: 19114984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impaired long-term expansion and self-renewal potential of pediatric acute myeloid leukemia-initiating cells by PTK787/ZK 222584.
    Weidenaar AC; Ter Elst A; Kampen KR; Meeuwsen-de Boer T; Kamps WA; Schuringa JJ; de Bont ES
    Mol Cancer Res; 2013 Apr; 11(4):339-48. PubMed ID: 23393162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacologic and genetic manipulation of MMP-2 and -9 affects retinal neovascularization in rodent models of OIR.
    Barnett JM; McCollum GW; Fowler JA; Duan JJ; Kay JD; Liu RQ; Bingaman DP; Penn JS
    Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):907-15. PubMed ID: 17251494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Geldanamycin treatment reduces neovascularization in a mouse model of retinopathy of prematurity.
    Kociok N; Krohne TU; Poulaki V; Joussen AM
    Graefes Arch Clin Exp Ophthalmol; 2007 Feb; 245(2):258-66. PubMed ID: 16741710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retinal vascular rescue of oxygen-induced retinopathy in mice by norrin.
    Tokunaga CC; Chen YH; Dailey W; Cheng M; Drenser KA
    Invest Ophthalmol Vis Sci; 2013 Jan; 54(1):222-9. PubMed ID: 23188723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Silencing of galectin-1 inhibits retinal neovascularization and ameliorates retinal hypoxia in a murine model of oxygen-induced ischemic retinopathy.
    Yang N; Zhang W; He T; Xing Y
    Exp Eye Res; 2017 Jun; 159():1-15. PubMed ID: 28257831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 inhibits aromatase.
    Banerjee S; Zvelebil M; Furet P; Mueller-Vieira U; Evans DB; Dowsett M; Martin LA
    Cancer Res; 2009 Jun; 69(11):4716-23. PubMed ID: 19435899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of neovascularization and expression shift of pro-/anti-angiogenic vascular endothelial growth factor isoforms after intravitreal bevacizumab injection in oxygen-induced-retinopathy mouse model.
    Shi X; Zhao M; Xie WK; Liang JH; Miao YF; DU W; Li XX
    Chin Med J (Engl); 2013 Jan; 126(2):345-52. PubMed ID: 23324288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential effects of bactericidal/permeability-increasing protein (BPI) analogues on retinal neovascularization and retinal pericyte growth.
    Rauniyar RK; Suzuma K; King AL; Aiello LP; King GL
    Invest Ophthalmol Vis Sci; 2002 Feb; 43(2):503-9. PubMed ID: 11818397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intra-hippocampal administration of the VEGF receptor blocker PTK787/ZK222584 impairs long-term memory.
    Pati S; Orsi SA; Moore AN; Dash PK
    Brain Res; 2009 Feb; 1256():85-91. PubMed ID: 19100245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia.
    Giles FJ; List AF; Carroll M; Cortes JE; Valickas J; Chen BL; Masson E; Jacques C; Laurent D; Albitar M; Feldman EJ; Roboz GJ
    Leuk Res; 2007 Jul; 31(7):891-7. PubMed ID: 17560285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.